A group that represents pharmacies that have been producing off-brand versions of GLP-1 weight-loss drugs just filed another ...

Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range ...

Novo Nordisk shares moved higher Tuesday after telehealth specialist Hims & Hers said that it would stop selling copycat versions of weight-loss drugs produced by the Danish company. Shares in the ...

We recently published a list of Jim Cramer Discusses These 12 Stocks & Trump DOJ’s Action Against Health Insurance Companies.

Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, ...

Eli Lilly announced a price reduction for its weight-loss drug Zepbound's vials by $50 or more, adapting to stiff competition ...

Eli Lilly has reduced the price of its weight-loss drug, Zepbound, to combat competition from compounding pharmacies and Novo ...

Medical treatments, including jabs used for weight loss, are monitored in part using the Medicines and Healthcare products ...

Eli Lilly & Co. said Tuesday it's cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will also ...

Since, Viking's clinical data remain strong, and the company aims to launch a phase 3 trial for the injectable version of ...

Spending on older medicines like metformin, used only for diabetes, declined. But that of popular GLP-1 drugs such as Novo ...

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...